Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.52
+0.10 (+0.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neogenomics Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
November 07, 2022
Via
ACCESSWIRE
If You Invested $1,000 In These 3 Crypto Tokens You Would Have This Much In Crypto Dividends
October 28, 2022
When navigating the cryptocurrency market it can be difficult to distinguish between the “s— tokens” and tokens that actually provide value through a utility.
Via
Benzinga
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
October 28, 2022
Via
ACCESSWIRE
Aaron's, Celestica, Medpace Holdings And Some Other Big Stocks Moving Higher On Tuesday
October 25, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 20, 2022
Thursday saw 177 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
September 07, 2022
Via
ACCESSWIRE
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
August 22, 2022
Via
Benzinga
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
October 26, 2022
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.
Via
Benzinga
Starbucks Plunges As Xi Jinping Consolidates Power: Here's What's Going On
October 24, 2022
Starbucks Corporation (NASDAQ: SBUX) was sliding about 6% lower on Monday in tandem with a number of China-based stocks.
Via
Benzinga
NeoGenomics: Q2 Earnings Insights
August 12, 2022
NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 4 Analyst Ratings Have To Say About NeoGenomics
August 10, 2022
NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter:
Via
Benzinga
NeoGenomics: Q2 Earnings Insights
August 09, 2022
NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
October 13, 2022
Via
ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022
August 26, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
August 22, 2022
Upgrades
Via
Benzinga
Target To $200? Here Are 5 Other Price Target Changes For Thursday
August 18, 2022
Raymond James raised the price target on Target Corporation (NYSE: TGT) from $190 to $200. However, Raymond James analyst Bobby Griffin maintained the stock with a Strong Buy. Target shares fell 0.1%...
Via
Benzinga
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
August 09, 2022
Via
ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
July 21, 2022
Via
ACCESSWIRE
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2022
Via
ACCESSWIRE
Earnings Scheduled For August 12, 2022
August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.
Via
Benzinga
NeoGenomics Announces Chief Executive Officer Appointment
July 21, 2022
Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
July 15, 2022
FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...
From
NeoGenomics, Inc.
Via
AccessWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
June 27, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
June 24, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
June 24, 2022
From
Law Offices of Frank R. Cruz
Via
Business Wire
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
June 21, 2022
FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms...
From
NeoGenomics, Inc.
Via
AccessWire
Lost Money in NeoGenomics, Inc.?
June 03, 2022
From
Gibbs Law Group
Via
Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
June 03, 2022
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
From
NeoGenomics, Inc.
Via
AccessWire
Analyst Ratings for NeoGenomics
June 03, 2022
Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.